Literature DB >> 11721635

Proteomics for studying cancer cells and the development of chemoresistance.

G Hütter1, P Sinha.   

Abstract

Extensive studies during the last decades have identified several mechanisms through which cells escape the cytotoxic effects of a variety of chemotherapeutic drugs. One type of drug resistance is called multidrug resistance (MDR), because selection with one anticancer drug leads to cross-resistance with a wide range of other drugs. These MDR cells express frequently plasma transport proteins like p-glycoprotein. But cellular resistance to chemotherapy is multifactorial and may be affected by the cell cycle stage and proliferation status, biochemical mechanisms such as detoxification, cellular drug transport, or DNA replication and repair mechanisms. Several laboratory techniques, such as polymerase chain reaction, immunocytochemistry, flow cytometry, blotting, and fluorescent microscopy have been used for the identification of MDR markers and mechanisms. We review the possibilities in studying cancer biology and development of chemoresistance in cancer treatment using the proteomic approach.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11721635     DOI: 10.1002/1615-9861(200110)1:10<1233::AID-PROT1233>3.0.CO;2-2

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  10 in total

1.  Serum/Plasma depletion with chicken immunoglobulin Y antibodies for proteomic analysis from multiple Mammalian species.

Authors:  Douglas Hinerfeld; David Innamorati; John Pirro; Sun W Tam
Journal:  J Biomol Tech       Date:  2004-09

2.  Clinical proteomics: present and future prospects.

Authors:  Nicole M Verrills
Journal:  Clin Biochem Rev       Date:  2006-05

3.  Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

Authors:  Xing-Chen Peng; Feng-Ming Gong; Meng Wei; Xi Chen; Ye Chen; Ke Cheng; Feng Gao; Feng Xu; Feng Bi; Ji-Yan Liu
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

4.  A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.

Authors:  Xingchen Peng; Fengming Gong; Gang Xie; Yuwei Zhao; Minghai Tang; Luoting Yu; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2011-01-18       Impact factor: 3.396

Review 5.  Mass spectrometry based targeted protein quantification: methods and applications.

Authors:  Sheng Pan; Ruedi Aebersold; Ru Chen; John Rush; David R Goodlett; Martin W McIntosh; Jing Zhang; Teresa A Brentnall
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

6.  Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.

Authors:  Ying Wang; Jen-Fu Chiu
Journal:  Met Based Drugs       Date:  2008

7.  Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp.

Authors:  Minzhi Zhao; Chunni Lei; Yadong Yang; Xiangli Bu; Huailei Ma; He Gong; Juan Liu; Xiangdong Fang; Zhiyuan Hu; Qiaojun Fang
Journal:  PLoS One       Date:  2015-07-16       Impact factor: 3.240

8.  Pathway analysis and transcriptomics improve protein identification by shotgun proteomics from samples comprising small number of cells--a benchmarking study.

Authors:  Jing Sun; Guang Lan Zhang; Siyang Li; Alexander R Ivanov; David Fenyo; Frederique Lisacek; Shashi K Murthy; Barry L Karger; Vladimir Brusic
Journal:  BMC Genomics       Date:  2014-12-08       Impact factor: 3.969

9.  Pygopus2 inhibits the efficacy of paclitaxel-induced apoptosis and induces multidrug resistance in human glioma cells.

Authors:  Cefan Zhou; Hongxia Cheng; Wenying Qin; Yi Zhang; Hui Xiong; Jing Yang; Huang Huang; Yefu Wang; Xing-Zhen Chen; Jingfeng Tang
Journal:  Oncotarget       Date:  2017-04-25

10.  Proteomics: A Study of Therapy Resistance in Cancer Cells.

Authors:  Hermann Lage
Journal:  EJIFCC       Date:  2005-05-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.